AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter

AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter

Abstract Background There is an urgent unmet clinical need for the identification of novel therapeutics for the treatment of COVID-19. A number of COVID-19 late phase trial platforms have been developed to investigate (often repurposed) drugs both in the UK and globally (e.g. RECOVERY led by the Uni...

Full description

Bibliographic Details
Main Authors: Gareth O. Griffiths, Richard FitzGerald, Thomas Jaki, Andrea Corkhill, Helen Reynolds, Sean Ewings, Susannah Condie, Emma Tilt, Lucy Johnson, Mike Radford, Catherine Simpson, Geoffrey Saunders, Sara Yeats, Pavel Mozgunov, Olana Tansley-Hancock, Karen Martin, Nichola Downs, Izabela Eberhart, Jonathan W. B. Martin, Cristiana Goncalves, Anna Song, Tom Fletcher, Kelly Byrne, David G. Lalloo, Andrew Owen, Michael Jacobs, Lauren Walker, Rebecca Lyon, Christie Woods, Jennifer Gibney, Justin Chiong, Nomathemba Chandiwana, Shevin Jacob, Mohammed Lamorde, Catherine Orrell, Munir Pirmohamed, Saye Khoo, on behalf of the AGILE investigators
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Trials
Subjects:
COVID-19
SARS-CoV-2
Randomised controlled trial
Platform study
Master protocol
Phase I/II, Bayesian
Online Access:https://doi.org/10.1186/s13063-021-05458-4

Internet

https://doi.org/10.1186/s13063-021-05458-4

Similar Items